
每年秋季,癌症相关话题都会在美国社会引发讨论热潮。秋季期间,各类防癌宣传活动、癌症幸存者故事接连涌现,不断提醒人们体检。这种关注意义重大。但今年,这场讨论还伴随着另一大转变:越来越多美国人开始借助人工智能解答自身健康疑问。
一项最新研究发现,76%的Z世代成年人和63%的千禧一代,如今将人工智能列为初级医疗保健咨询的首选,其优先级甚至高于面诊医生。
只需短短几秒,我们就能搜索症状、理解医学术语,并进一步了解潜在风险。若能善加利用,人工智能无疑是高效实用的工具,但掌握更多信息,并不等同于知道下一步该怎么做。在癌症问题上尤其如此。持续接受医生诊疗能更精准识别那些看似无关、实则预示重症的症状。这就是为什么人工智能应充当医疗保健“助手”,而不能“主导诊疗决策”。
身为《财富》美国500强企业总裁,要将理念转化为决策,再将决策转化为行动。在美国家庭人寿保险公司担任管理岗位二十余年后,我认识到:缺乏指导的行动,很快就会沦为不作为。最佳对策就是制定稳妥战略,形成切实可行的保健计划。
而在个人健康管理这件事上,我们却常常忽视了这一点。
尽管防癌宣传已开展数十年,仍有近三分之二的美国人会推迟接受推荐的健康筛查。这并不是因为人们不了解筛查的重要性,而是生活琐事缠身。我们也知道,人们会担心检查结果,或是自我安慰:身体没有不适,就没必要体检。
技术有助于消除部分障碍,人工智能可成为该计划的一环:帮人们理解不同筛查项目的区别,或是提前整理面诊时想问医生的问题。但人工智能的能力终究有限。
当你犹豫不决、迟迟不愿赴诊时,人工智能无法督促你前往医院;它无法进行乳腺X光检查或结肠镜检查,也无法亲自查看你的病史,从而推断出潜在病症,更无法取代你信任之人那句关切的询问:“你去查那个项目了吗?”
另一项关于癌症筛查行为的研究也印证了这一点:大多数美国人认为,鼓励亲人接受筛查是爱的体现,并表示这种鼓励会改变他们自身的就医行为。这提醒我们,最有效的健康干预,往往不是屏幕上的信息,而是来自身边熟悉并关心你的人。
和许多家庭一样,我的家人也曾深受癌症之苦。我亲眼目睹亲友面对诊断、治疗,以及随之而来的不确定性。正是这些经历,让我持续发声,使人们不再犹豫、付诸行动。
坦白来讲,这也是美国家庭人寿保险公司的商业模式:当有人错过筛查、确诊太晚,家庭需要承担医疗保险无法完全覆盖的开销时,我们的价值就得以体现。人工智能相关讨论对我们而言并非空洞理论,它实实在在反映在理赔数据中。
您可以践行这一原则,做自身健康的第一责任人。正因如此,人工智能应充当医疗保健助手,而不能主导诊疗决策。(财富中文网)
弗吉尔·米勒(Virgil Miller)现任美国家庭人寿保险公司(Aflac Incorporated)及其美国公司(Aflac U.S.)总裁,该公司是美国和日本领先的癌症保险提供商。
Fortune.com上发表的评论文章中表达的观点,仅代表作者本人的观点,不代表《财富》杂志的观点和立场。
译者:中慧言-王芳
每年秋季,癌症相关话题都会在美国社会引发讨论热潮。秋季期间,各类防癌宣传活动、癌症幸存者故事接连涌现,不断提醒人们体检。这种关注意义重大。但今年,这场讨论还伴随着另一大转变:越来越多美国人开始借助人工智能解答自身健康疑问。
一项最新研究发现,76%的Z世代成年人和63%的千禧一代,如今将人工智能列为初级医疗保健咨询的首选,其优先级甚至高于面诊医生。
只需短短几秒,我们就能搜索症状、理解医学术语,并进一步了解潜在风险。若能善加利用,人工智能无疑是高效实用的工具,但掌握更多信息,并不等同于知道下一步该怎么做。在癌症问题上尤其如此。持续接受医生诊疗能更精准识别那些看似无关、实则预示重症的症状。这就是为什么人工智能应充当医疗保健“助手”,而不能“主导诊疗决策”。
身为《财富》美国500强企业总裁,要将理念转化为决策,再将决策转化为行动。在美国家庭人寿保险公司担任管理岗位二十余年后,我认识到:缺乏指导的行动,很快就会沦为不作为。最佳对策就是制定稳妥战略,形成切实可行的保健计划。
而在个人健康管理这件事上,我们却常常忽视了这一点。
尽管防癌宣传已开展数十年,仍有近三分之二的美国人会推迟接受推荐的健康筛查。这并不是因为人们不了解筛查的重要性,而是生活琐事缠身。我们也知道,人们会担心检查结果,或是自我安慰:身体没有不适,就没必要体检。
技术有助于消除部分障碍,人工智能可成为该计划的一环:帮人们理解不同筛查项目的区别,或是提前整理面诊时想问医生的问题。但人工智能的能力终究有限。
当你犹豫不决、迟迟不愿赴诊时,人工智能无法督促你前往医院;它无法进行乳腺X光检查或结肠镜检查,也无法亲自查看你的病史,从而推断出潜在病症,更无法取代你信任之人那句关切的询问:“你去查那个项目了吗?”
另一项关于癌症筛查行为的研究也印证了这一点:大多数美国人认为,鼓励亲人接受筛查是爱的体现,并表示这种鼓励会改变他们自身的就医行为。这提醒我们,最有效的健康干预,往往不是屏幕上的信息,而是来自身边熟悉并关心你的人。
和许多家庭一样,我的家人也曾深受癌症之苦。我亲眼目睹亲友面对诊断、治疗,以及随之而来的不确定性。正是这些经历,让我持续发声,使人们不再犹豫、付诸行动。
坦白来讲,这也是美国家庭人寿保险公司的商业模式:当有人错过筛查、确诊太晚,家庭需要承担医疗保险无法完全覆盖的开销时,我们的价值就得以体现。人工智能相关讨论对我们而言并非空洞理论,它实实在在反映在理赔数据中。
您可以践行这一原则,做自身健康的第一责任人。正因如此,人工智能应充当医疗保健助手,而不能主导诊疗决策。(财富中文网)
弗吉尔·米勒(Virgil Miller)现任美国家庭人寿保险公司(Aflac Incorporated)及其美国公司(Aflac U.S.)总裁,该公司是美国和日本领先的癌症保险提供商。
Fortune.com上发表的评论文章中表达的观点,仅代表作者本人的观点,不代表《财富》杂志的观点和立场。
译者:中慧言-王芳
Every fall, cancer starts sounding louder in the national conversation. The months between summer and winter bring multiple awareness campaigns, survivor stories, and reminders to get checked. That attention really matters. This year, however, that conversation is happening alongside another major shift: More Americans are turning to artificial intelligence (AI) for answers about their health.
A recent study found that 76% of Gen Z adults and 63% of millennials now turn to AI as their first line of primary healthcare — before ever seeing a doctor.
In seconds, we can search for symptoms, understand medical terminology and learn more about potential risks. Used responsibly, AI can be an extraordinarily useful tool, but knowing more is not the same as knowing what to do next. This is especially true when it comes to cancer. Consistent physician care can more accurately identify signs of more serious conditions associated with symptoms that might not always seem relevant. That is why AI should copilot but not drive our healthcare.
Being president of a Fortune 500 company means turning concepts into decisions, and decisions into action. After more than two decades in leadership roles at Aflac, I have learned that action without guidance can quickly turn into inaction. The best cure for that is a solid strategy that results in a viable care plan.
And this is where, when it comes to our own healthcare, we continue to fall short.
Despite decades of awareness campaigns, nearly two-thirds of Americans still delay recommended health screenings. It is not because people don’t understand that screenings matter; rather, life just gets busy. We also know that people worry about what they might learn, or convince themselves that because they feel fine, there is no reason to get checked.
Technology can help address some of those barriers. AI can be a component of the plan. It can help someone understand the difference between screening options or help prepare questions before a doctor’s appointment. But there is a limit to what AI technology can do.
AI cannot take you to an appointment when you are hemming and hawing about going. It cannot perform a mammogram or a colonoscopy. And it cannot personally view your health history and connect the dots on a possible condition that didn’t exist before, and certainly cannot replace the voice of someone you trust asking, “Did you get that checked?”
Separate research on cancer-screening behavior backs this up: most Americans describe encouraging a loved one to get screened as an act of love, and say that encouragement changes their own behavior. It’s a reminder that the most powerful health intervention tool is not information coming out of a screen. It often can be someone who knows and cares about you.
Like so many families, mine has been touched by cancer, and I have watched loved ones and friends navigate diagnoses, treatment and the uncertainty that comes with both. Those experiences are why I will continue to raise my voice to help move people from uncertainty to action.
That’s also, frankly, Aflac’s business model: we exist because a screening gets missed, a diagnosis comes late, and a family needs help covering what health insurance alone doesn’t. The AI conversation isn’t abstract for us — it shows up in our claims data.
You can apply this principle by being the leader of your health. That is why AI should be the copilot but not the driver of our healthcare.
Virgil Miller is president of Aflac Incorporated and Aflac U.S., a leading provider of cancer insurance in the United States and Japan.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.